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ABSTRACT 
The purpose of this study is to test whether or not drinking moderate quantities of 
carbonated soft drinks has any effects on diabetic retinopathy in patients with Insulin-
dependent diabetes Mellitus. 
Based on personal observations, diabetic retinopathy, especially if accompanied with 
diabetic macular edema, seems to improve when discontinuing moderate quantities of 
carbonated soft mdrinks1. Therefore it was hypothesized that carbonated beverage 
consumption may have an adverse effect on patients with diabetic retinopathy, 
specifically those with diabetic macular edema. 
Diabetic Macular Edema 
Dietary salt is responsible for raising blood pressure, thickens and stiffens conduit 
arteries and thickens and narrows resistance arteries. It also increases the number of 
strokes, and the tendency for platelet aggregation37. An increased total body sodium and 
enhanced vascular reactivity are found in people with diabetes and most type 2 diabetics 
are salt sensitive. Similar to a subset of patients with essential hypertension, type 2 
diabetics manifest dietary salt-induced exacerbation ofhypertension36. 
Sympathetic nerve overactivity is crucial in the pathogenesis of hypertension in diabetes. 
It is related to the activation of the rennin-angiotensin-aldosterone (RAA) system in. 
Sympathetic overactivity stimulates RAA activity, promotes sodium reabsorption, and 
increases heart rate, stroke volume, and peripheral vascular resistnce, thus inducing 
hypertension and increasing cardiovascular risk38 . 
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Diabetic Retinopathy 
Diabetic retinopathy remains a major cause ofloss ofvision.2 Overall, diabetic 
retinopathy is estimated to be the most frequent cause of new blindness in the U.S. 
among adults between the age of20-74 years8. Diabetic retinopathy is characterized by 
microaneurysms, hemorrhages, and lipid accumulation referred to as hard exudates, 
within the retina. Microaneurysms are thin-walled dilations of the capillaries that develop 
in diabetic patients as the pericyte cells which line the capillaries, die off and weaken the 
capillaries, causing a "ballooning", of the capillaries, or microaneurysm. Macular edema 
(retinal thickening) is an important manifestation of diabetic retinopathy as it is the 
leading cause of legal blindness in diabetic patients. Retinal thickening of macular edema 
is a result of intercellular fluid derived from both leaking micro aneurysms and diffuse 
capillary leakage9. patients with diabetic macular edema have a significant impaired 
visual acuity. Diabetic maculopathy is closely associated with diabetic nephropathy and 
neuropathy and with several atherosclerotic fisk factors which suggest that these factors 
may have an important role in the pathogenesis ofmaculopathy4• 
Medical treatment of macular edema with carbonic anhydrase inhibitors have been 
known effective treatment of cystoid macular edema in patients with diabetic macular .L 
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edema in nonproliferative retinopathy, even though mechanisms remain obscure20• 
although it may facilitate the transport of water across the retinal pigment epithelium 
from the subretinal space24. Carbonic anhydrase inhibitors have also been shown to have 
other direct effects both on retinal and retinal pigment epithelial function by inducing an 
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acidification of the subretinal space, a decrease ofthe standing potential as well as an 
increase in the retinal advesiveness25 .. The enzyme carbonic anhydrase catalyzes the 
conversion of carbon dioxide and hydroxide ion into bicarbonate22.Acetazolamide, a 
diuretic, is a carbonic anhydrase inhibitor, primarily effects the kidneys by inhibiting 
carbonic anhydrase. Its mechanism of action is inhibits caarbonic anhydrase, which in 
turns catalzses the haydration of bicarbonate at the proximal tubule in the kidneys, 
facilitating the resorption of virtually all of the sodium21 . By inhibiting hydrogen ion 
secretion by the renal tubules, carbonic anhydrase inhibitors cause increased excretion of 
electrolytes, sodium, potassium, bicarbonate, and H20, thus producing alkaline diuresis23• 
As carbonic anyhdrase inhibitors increase the excretion of sodium, potassium, 
I bicarbonate, and water, and improve diabetic macular edema, discontinuation of 
carbonated soft drinks (which contain the above electrolytes), may have a similar 
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effect1.Carbonated soft drinks have been part of American lifestyle for more than 100 
years. Soft drinks contain between 90% water in regular soft drinks, up to 99% water in 
diet soft drinks. Carbon dioxide is the essential ingredient in all carbonated beverages. 
Soft drinks also contain flavors, coloring, caffeine, acidulants, preservatives, potassium, 
phosphorous, sodium, sucrose or high fructose com syrup in regular (non-diet) soft 
drinks, and aspartame, saccharin, sucralose and acesulfame Kin diet soft drinks. One out 
of every four beverages consumed in America is a carbonated soft drink, which averages 
io over 57 gallons of soft drinks per year for every man, woman and child 7. T'nis is 
equivalent to more than 576 12-oz. servings per year or 1.6 12 oz. cans per day for every 
man, woman, and child28.Carbonated soft drinks account for more than 27% of 
Americans' beverage consumption7 . Artificially sweetened diet sodas account for 24% of 
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sales29. Carbonated soft drinks are the biggest source of refmed sugars in the American 
Caffeine in soft drinks 
Caffeine in soft drinks varies by brand, from 0 mg. in caffeine-free and 7-Up, to 58mg 
per 12 oz.in Josta Cola. Most standard brands (Pepsi, Coca-cola) contain between 37.5 to 
46.5 mg. per 12. can27 
Caffeine, sodium, hypertension, and diabetes 
Diabetes and hypertension are both relatively common diseases in westernized countries. I L 
Both diseases increase with age. Hypertension is twice as frequent in diabetic patient than I 
in the general population38. Essential hypertension accounts for the majority of 
hypertension in people with type 2 diabetes, which what? Type 2 diabetes or essential 
hypertension?] constitutes more than 90% of those with dual diagnosis of diabetes and 
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hypertension. The benefit conferred per mmHg of Blood pressure reduction is greater in 
persons with type 2 diabetes than with hypertensive patients without diabetes. Recent 
guidelines have recommended that target blood pressure levels in patients with diabetes 
should be lower than in other hypertensive groups31 . It is currently recommended that 
individuals with diabetes maintain a blood pressure ofless than 130/85 to maximize renal 
protection33. An increased total body sodium and enhanced vascular reactivity are found 
in people with diabetes, and most type 2 diabetic patients are salt sensitive31 . 
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Caffeine raises blood pressure by elevating vascular resistance, and this effect is more 
pronounced and prolonged in hypertensive patients than in normotensives32. Regular 
coffee drinking raised blood pressure in older hypertensives35 . 
Known Risk Factors in Diabetic Retinopathy 
The best predictor of diabetic retinopathy is the duration of the disease 10. Patients who 
have had insulin-dependent diabetes mellitus (IDDM) for 5 or less years rarely show 
evidence of diabetic retinopathy11 • However, 27 of those who have had IDDM for 5-l 0 
years and 71 to 90% of those who have had IDDM greater than 10 years have diabetic 
retinopathy. After the diagnosis ofNon-insulin-dependent diabetes mellitus (NIDDM), 
67% of patients had retinopathy and 10% had proliferative diabetic retinopathy (PDR) 12. 
Systemic Factors 
Control of blood glucose 
The Diabetes Control and Complications Trial (DCCT), published in 1993, was the first 
large, scientific, and clinical trial demonstrated a marked reduction in the development 
and progression of diabetic complications in intensively treated patients3. More recently, 
the U.K. Prospective Diabetes Study confirmed that intensively controlled patients with 
type 2 diabetes had a significantly reduction in microvascular complications 4. 
Renal Disease 
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Patients with renal disease (proteinurea, elevated blood urea nitrogen, and elevated blood 
creatine) almost always have retinopathy13 . However, only 35% of patients with 
retinopathy have proteinuria, elevated blood urea nitrogen, or elevated creatine14. [I don't 
understand this] 
Body Mass Index (BMI) 
Body mass index, or BMI, [higher? Lower?]is a positive risk factor for diabetic 
retinopathy19. Body mass index is expressed as weight in kilograms divided by the square 
of the height in meters. 
Systemic Hypertension 
Elevated systolic blood pressure is a moderate risk for diabetic retinopathy14, whereas 
other studies have shown that diastolic blood pressure is important for the development 
of retinopathy in type 1 diabetes15. Control of systemic hypertension reduces the risk of 
new onset diabetic retinopathy and slows the progression of existing diabetic 
retinopathy15. Pulse raterate [high? Low?] may be an indicator of overall risk of diabetic 
retinopathy, but is not an independent association with the condition16. 
Race 
The prevalence of diabetic retinopathy is more prevalent in blacks compared to whites 17• 
In addition, blacks have a higher rate of severe macular edema and blindness, probably 
because of a higher incidence of severe systemic hypertension and because of poorer 
medical care18• 
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These studies demonstrate evidence that good metabolic control protects diabetic patients 
against complications. However, clinicians are faced with individual variability of 
diabetic patients in their practices, often wonder why some patients under good metabolic 
control develop complications while others remain free of complications, despite poorly 
controlled diabetic , remaincontrol5. Studies have shown that retinopathy develops in 
about 10% of patients with type 1 diabetes under good metabolic control, whereas over 
40% of patients with type 1 diabetes remain retinopathy-free despite poor metabolic 
The present study is to observe if moderate consumption of carbonated soft drinks has b I any effects on diabetic retinopathy. 
RESEARCH DESIGN AND METHODS 
ii'-
Records from a retina specialist's office were reviewed. Only patients with insulin-
dependent diabetes mellitus with diabetic retinopathy and macular edema during the 
period of 1998 -2003 were selected. . A computer program was written in Hypercard 2.4 
(Apple™) was designed to perform searches in patient records for all patients within the l 
retina practice that include patients with IDDM, have documented word with "sodas" or 
"carbonated drinks" and a diagnosis of "macular edema". All patients had diabetic 
retinopathy at baseline and patients with previous laser treatments at initial visit were 
excluded. Efforts were made to include women and minorities. A retrospective or 
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historical cohort study design was within on patients within the retina clinic; using 
patients with insulin-dependent diabetes mellitus with diabetic retinopathy who drink 
carbonated drinks compared to a similar group of diabetic patients with retinopathy, but 
did not drink carbonated beverages. The prevalence of diabetic macular edema in each 
group was then compared. 
From approximately I 0,000 medical records, about 3,500 patients with Insulin-dependent 
Diabetes Mellitus (IDDM) were extracted. Of those patients, 1,849 patient records had 
"soda" or "carbonated beverages" documented within the record. I ,278 patients had 
macular edema and drank at least I -12 oz. can of soda per day, and had the diagnosis of 
diabetic macular edema. 158 patients drank at least I can of soda per day and did have 
diabetic macular edema. 355 patients had diabetic macular edema, but did not drink 
sodas. 49 patients had IDDM and no macular edema, and had documented "no sodas" or 
"does not drink sodas" in their medical records. 
Calculation of the prevalence of disease in persons with exposure (sodas) and compare it 
with the prevalence of disease (macular edema) without exposure. Odds Ratio in a 2 X 2 
table was tabulated and calculated (table I). 
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Table I. 
Sodas 
No sodas 
Odds Ratio • Macular Edema and Sodas 
Controls 
Macular edema No macular edema 
(exposed) I 12781 1581 
(not exposed) 355 46 
Odds Ratio= a/c = 
bid 
Odds Ratio= 58788 
56090 
Odds Ratio= 1.048101266 
ad 
be 
1: 1: 
In addition, a survey was performed to estimate the carbonated beverage dinking 
habits of diabetics, compared to non-diabetics. The survey included categories of age, 
sex, race, no. of years having diabetes if diabetic. Efforts were made to include an 
adequate sample of race, age and both sexes. Carbonated soft drink consumption was 
estimated per day, soda use was categorized as regular or diet, caffeinated or caffeine-
free. Data was entered using Access (Microsoft®), statistics were calculated, including 
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average soda consumption, categories of sodas were tabulated, and pie graphs were 
generated. 
The study design has been submitted to the Institutional Review Board for approval. 
Definition of carbonated soft drink users 
In this study, the definition of a carbonate soft drink user was anyone who drinks 1 or 
more, 12 oz. cans of soda or equivalent, each day. 
Results 
Of the sample surveyed, 88% of non-diabetics drank sodas, averaging 1.4 sodas per day, 
while 70% of diabetics drank sodas, averaging 1.4% sodas per day. 60% of non-diabetics 
j___ 
~ drink regular sodas, 28% drank diet, while in the diabetic group, 52% drank diet, and 
18% drank regular sodas. (Figures 1 and 2). 
' 
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Fig.l 
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Risk- Odds Ratio 
The Odds Ratio in our group studied, or the ratio of the odds of development of disease 
in exposed (to sodas) persons to the odds of development of disease (macular edema) in 
non-exposed (no sodas), was 1.05 demonstrating that there is not an apparent association 
between soda drinking and diabetic macular edema. If the exposure is not related to the 
disease, the odds ratio will be equal to 1. 
Conclusions 
From this study, there is no clear association between drinking sodas and diabetic 
macular edema, demonstrating a spurious association from observation noted above 
within the retina clinic. However, due to confounding, we cannot rule out an association 
between macular edema and soda consumption. As soda consumption was not quantified, 
no dose-response was measured. Errors from selection bias may have a major impact on 
the internal validity of the study. Information bias or inaccuracies of data acquisition 
may have, at times, misclassified information regarding exposure status. Further studies-
prospective, case-controlled, and clinical trials studies are needed for more conclusive 
evidence whether there is no association between carbonated beverage consumption and 
diabetic macular edema. 
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